Related Experiment Video
Updated: Jun 22, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis
M Camiña-Tato1, C Morcillo-Suárez, A Navarro
1Centre d'Esclerosi Múltiple de Catalunya, CEM-Cat, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron (HUVH), Pg. Vall d'Hebron, Barcelona, Spain.
Journal of Neuroimmunology
|June 12, 2009
Summary
The B-cell translocation gene 1 (BTG1) may play a role in multiple sclerosis (MS) susceptibility. Specific BTG1 gene variations are linked to an increased risk of developing relapse-onset MS.
Area of Science:
- Genetics
- Immunology
- Neuroscience
Background:
- Multiple sclerosis (MS) is a complex autoimmune disease affecting the central nervous system.
- Genetic factors are known to contribute to MS susceptibility, but specific genes remain under investigation.
- The B-cell translocation gene 1 (BTG1) is involved in cellular apoptosis and has been explored as a potential MS susceptibility gene.
Purpose of the Study:
- To investigate the association between B-cell translocation gene 1 (BTG1) polymorphisms and the risk of developing multiple sclerosis (MS).
- To examine the role of specific single nucleotide polymorphisms (SNPs) within the BTG1 gene in MS susceptibility, particularly in relapse-onset MS.
Main Methods:
- Genotyping of two single nucleotide polymorphisms (SNPs), rs731652 and rs12694, within the BTG1 gene.
- Case-control study design involving 550 patients with multiple sclerosis and 548 healthy controls.
- Statistical analysis to assess allele and genotype frequencies and identify risk haplotypes.
Main Results:
- Significant associations were found for SNP rs731652 at both the allele and genotype levels in patients with relapse-onset MS compared to controls.
- A specific risk haplotype within the BTG1 gene was identified and associated with relapse-onset MS.
- No significant associations were reported for SNP rs12694.
Conclusions:
- Polymorphisms in the B-cell translocation gene 1 (BTG1) may contribute to the genetic predisposition for multiple sclerosis (MS).
- The findings suggest a potential role for BTG1 in the pathogenesis of relapse-onset MS.
- Further research is warranted to elucidate the functional mechanisms linking BTG1 variations to MS.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...